The U.S. Food and Drug Administration approved Bravecto Quantum (fluralaner for extended-release injectable suspension), for use in dogs and puppies 6 months of age and older. This is the first FDA-approved drug that protects dogs against fleas and ticks for 8 to 12 months.
Bravecto Quantum must only be prescribed by a licensed veterinarian because professional expertise is required to properly administer the injection, to monitor for and respond to adverse reactions, to advise dog owners regarding use in breeding dogs and to define the appropriate treatment interval (8 versus 12 months) based on the species of ticks the dog is likely to encounter.
Fluralaner, the active ingredient in Bravecto Quantum, belongs to a class of antiparasitic drugs called isoxazolines. Several products containing isoxazolines are approved for the treatment and control of fleas and certain ticks in dogs and cats. These products generally protect against fleas and ticks for 1 month .
Although isoxazoline products are commonly used and safe for most dogs and cats, the products have been associated with neurologic adverse reactions, including muscle tremors, ataxia, and seizures in some dogs and cats. Pet owners should consult with a veterinarian to determine whether a product in the isoxazoline class is appropriate for their pet.
For more information, read the original press release.
For more news from the world of long-acting therapeutics, sign up to the CELT's LONGEVITY mailing list here for regular updates.